Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs

Area of Science:

• Biochemistry
• Pharmacology
• Clinical Chemistry

Background:

• Low molecular weight heparins (LMWHs) are standard anticoagulants for venous thromboembolism.
• Monitoring anticoagulant effects via anti-Factor Xa (anti-FXa) assays is crucial in clinical diagnostics.
• Existing assays require comparison for optimal clinical application.

Purpose of the Study:

• To develop and validate a novel fluorogenic anti-FXa assay.
• To determine the sensitivity and assay range for LMWHs (enoxaparin, tinzaparin) and a heparinoid (danaparoid).
• To compare the new assay with a previously established fluorogenic anti-FXa assay.

Main Methods:

• Development of a fluorogenic anti-FXa assay using a commercially available substrate (Mes-D-LGR-ANSN).
• Assay principle involves complexation of heparinised plasma with exogenous Factor Xa and the fluorogenic substrate.
• Testing with spiked plasma samples and comparison with a peptide-based fluorogenic assay (Pefafluor FXa).

Main Results:

• The fluorogenic assay demonstrated statistically sensitive ranges: 0-0.4 U mL⁻¹ for enoxaparin/tinzaparin and 0-0.2 U mL⁻¹ for danaparoid.
• Assay variation was consistently below 10.5%.
• Comparisons with the Pefafluor FXa assay evaluated fluorescence intensity, lag times, and anticoagulant sensitivity.

Conclusions:

• The developed fluorogenic anti-FXa assay is a sensitive tool for monitoring LMWHs and danaparoid.
• This assay provides a reliable method for routine laboratory use in anticoagulant monitoring.
• Further comparison with existing methods confirms its potential clinical utility.